Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | EBP | Q15125 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | EBPL | Q9BY08 | 1/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [11C]Sa4503 SCHEMBL968642 | 1.00 | SIGMAR1 (1.00) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| [11C]Sa4503 SCHEMBL29358694 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| [11C]Sa4503 SCHEMBL1299046 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8088187 | 0.99 | SIGMAR1 (0.97) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8083210 | 0.97 | SIGMAR1 (0.95) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8086559 | 0.96 | SIGMAR1 (0.92) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8075024 | 0.96 | SIGMAR1 (0.92) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| Hydrochloric Acid SCHEMBL8086545 | 0.95 | SIGMAR1 (0.90) | SIGMAR1EBPTMEM97EBPLABCB1 | |
| SCHEMBL8075010 | 0.94 | SIGMAR1 (0.89) | SIGMAR1EBPTMEM97EBPL | |
| Hydrochloric Acid SCHEMBL8074974 | 0.94 | SIGMAR1 (0.88) | SIGMAR1EBPTMEM97EBPLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719488-A1 | EXTRACELLULAR VESICLES FOR DRUG DELIVERY AND USES THEREOF | UMC Utrecht Holding B.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| EP-4562184-A2 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | Anavex Life Sciences Corp. (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4561566-A1 | COMPOSITIONS AND METHODS FOR PREVENTION OF COGNITIVE DECLINE CAUSED BY DEGENERATIVE DISEASES | Anavex Life Sciences Corp. (US) | 2025-06-04 | — | — | EP | claimed |
| CN-119997948-A | Compositions and methods for preventing cognitive decline caused by degenerative diseases | 阿纳韦克斯生命科学公司 | 2025-05-13 | — | — | CN | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240417798-A1 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | ANAVEX LIFE SCIENCES CORP. | 2024-12-19 | — | — | US | claimed |
| WO-2024248610-A1 | EXTRACELLULAR VESICLES FOR DRUG DELIVERY AND USES THEREOF. | UMC UTRECHT HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | claimed |
| CN-119004305-A | Deep learning-based method for detecting abnormal industrial data under chain | 桂林电子科技大学 | 2024-11-22 | — | — | CN | claimed |
| EP-4436573-A1 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | Anavex Life Sciences Corp. (US) | 2024-10-02 | — | — | EP | claimed |
| CN-117418037-A | Primer combination for rapidly detecting genotypes of multiple functional loci of peppers and application of primer combination | 北京市农林科学院 | 2024-01-19 | — | — | CN | claimed |
| US-20230303697-A1 | Antiaging effect of Intradermal Administration of Immune Checkpoint Inhibitors | MYKARA, INC. (US) | 2023-09-28 | — | — | US | claimed |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | UNM RAINFOREST INNOVATIONS (US) | 2023-08-24 | — | — | US | claimed |
| WO-2023101866-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-08 | — | — | WO | claimed |
| WO-2023097029-A1 | THERAPY SELECTION AND TREATMENT OF NEURODEGENERATIVE DISORDERS | ANAVEX LIFE SCIENCES CORP. (US) | 2023-06-01 | — | — | WO | claimed |
| US-20230165810-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-06-01 | — | — | US | claimed |
| WO-2023034803-A1 | METHODS FOR TREATMENT OF FIBROSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| WO-2022169961-A1 | SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-11 | — | — | WO | claimed |
| US-20220226278-A1 | OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT | ANAVEX LIFE SCIENCES CORP. (US) | 2022-07-21 | — | — | US | claimed |
| US-20220023291-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165810-A1 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | SIGMAR1, HTR1A, HTR1E | SIGMAR1 1/4885EBP 1489/4885TMEM97 13/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | SIGMAR1 554/4885EBP 3050/4885TMEM97 2428/4885 |
| US-20220023291-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | SIGMAR1, OPRL1, FPR1 | SIGMAR1 1/4885EBP 631/4885TMEM97 255/4885 |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | SARS1, SQSTM1, ATG4A | SIGMAR1 2480/4885EBP 524/4885TMEM97 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.